Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study

Emma Gannan; Jeremy Khoo; Sophie S Nightingale; Thomas Surya Suhardja; Jocelyn Lippey; Holly Keane; Kian Jin Tan; David Clouston; Alexandra Gorelik; Gregory Bruce Mann; Jane Fox; The Melbourne Breast Group; David Speakman

doi:10.1111/tbj.12595

Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study

Emma Gannan, Jeremy Khoo, Sophie S Nightingale, Thomas Surya Suhardja, Jocelyn Lippey, Holly Keane, Kian Jin Tan, David Clouston, Alexandra Gorelik, Gregory Bruce Mann, Jane Fox, The Melbourne Breast Group, David Speakman

Research output: Contribution to journal › Article › Research › peer-review

9 Citations (Scopus)

Abstract

To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.

Original language	English
Pages (from-to)	413-419
Number of pages	7
Journal	The Breast Journal
Volume	22
Issue number	4
DOIs	https://doi.org/10.1111/tbj.12595
Publication status	Published - 1 Jul 2016

Keywords

ACOSOG Z0011 trial
axillary lymph node dissection
breast cancer
sentinel lymph node biopsy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/tbj.12595

Cite this

@article{477642e42b57466eaa36f2a16cb0a255,

title = "Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study",

abstract = "To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.",

keywords = "ACOSOG Z0011 trial, axillary lymph node dissection, breast cancer, sentinel lymph node biopsy",

author = "Emma Gannan and Jeremy Khoo and Nightingale, {Sophie S} and Suhardja, {Thomas Surya} and Jocelyn Lippey and Holly Keane and Tan, {Kian Jin} and David Clouston and Alexandra Gorelik and Mann, {Gregory Bruce} and Jane Fox and {The Melbourne Breast Group} and David Speakman",

year = "2016",

month = jul,

day = "1",

doi = "10.1111/tbj.12595",

language = "English",

volume = "22",

pages = "413--419",

journal = "The Breast Journal",

issn = "1075-122X",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Management of Early Node-Positive Breast Cancer in Australia

T2 - A Multicentre Study

AU - Gannan, Emma

AU - Khoo, Jeremy

AU - Nightingale, Sophie S

AU - Suhardja, Thomas Surya

AU - Lippey, Jocelyn

AU - Keane, Holly

AU - Tan, Kian Jin

AU - Clouston, David

AU - Gorelik, Alexandra

AU - Mann, Gregory Bruce

AU - Fox, Jane

AU - The Melbourne Breast Group

AU - Speakman, David

PY - 2016/7/1

Y1 - 2016/7/1

N2 - To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.

AB - To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.

KW - ACOSOG Z0011 trial

KW - axillary lymph node dissection

KW - breast cancer

KW - sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84977674221&partnerID=8YFLogxK

U2 - 10.1111/tbj.12595

DO - 10.1111/tbj.12595

M3 - Article

C2 - 27095381

AN - SCOPUS:84977674221

SN - 1075-122X

VL - 22

SP - 413

EP - 419

JO - The Breast Journal

JF - The Breast Journal

IS - 4

ER -

Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this